See feature article below: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)
Broad Street Alerts recent profiles and track record, 642% in verifiable potential gains for our members on 3 recent small cap alerts alone!
May 9th, 2016-(NYSE-MKT: MGT) opened at .64/share and hit over $4.15/share within 8 days for potential gains of 548% for our members.
May 23rd, 2016 (NYSE-MKT: XXII) opened at $.78/share and hit $.94/share within 2 days for potential gains of 20% for our members.
May 26th, 2016 (NASDAQ: CETX) opened at $2.00/share and hit $3.50/share within 10 days for potential gains of 74% for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Report For: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)
PDUFA Date: 07/19/2016
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)‘s stock had its “buy” rating reissued by equities researchers at Jefferies Group in a note issued to investors on Friday.
Progenics Pharmaceuticals (NASDAQ:PGNX) opened at 4.57 on Friday. Progenics Pharmaceuticals has a 1-year low of $3.61 and a 1-year high of $11.15. The stock’s market capitalization is $319.65 million. The company has a 50-day moving average price of $4.97 and a 200 day moving average price of $4.93.
Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.05. The company earned $2.50 million during the quarter, compared to analysts’ expectations of $3.27 million. The firm’s revenue was up 908.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.15) earnings per share. On average, equities analysts predict that Progenics Pharmaceuticals will post $0.12 EPS for the current year.
Other research analysts have also issued research reports about the company. Brean Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Progenics Pharmaceuticals in a research report on Tuesday, March 15th. Zacks Investment Research cut Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Progenics Pharmaceuticals in a research note on Monday, April 4th. Finally, BTIG Research decreased their price objective on shares of Progenics Pharmaceuticals from $12.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday, March 15th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $10.35.
A number of hedge funds and institutional investors recently modified their holdings of PGNX. BlackRock Fund Advisors increased its position in shares of Progenics Pharmaceuticals by 0.8% in the first quarter. BlackRock Fund Advisors now owns 2,725,796 shares of the company’s stock worth $11,884,000 after buying an additional 21,002 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in Progenics Pharmaceuticals by 0.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,794,275 shares of the company’s stock worth $7,823,000 after buying an additional 7,853 shares during the last quarter. Numeric Investors LLC boosted its stake in Progenics Pharmaceuticals by 47.8% in the fourth quarter. Numeric Investors LLC now owns 897,170 shares of the company’s stock worth $5,500,000 after buying an additional 290,299 shares during the last quarter. Rice Hall James & Associates LLC boosted its stake in Progenics Pharmaceuticals by 85.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 891,672 shares of the company’s stock worth $5,466,000 after buying an additional 409,618 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. boosted its stake in Progenics Pharmaceuticals by 5.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 607,900 shares of the company’s stock worth $3,726,000 after buying an additional 29,200 shares during the last quarter.
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.
Source – Web Breaking News
Broadstreetalerts.com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. SCS LLC has been compensated twenty thousand dollars cash via bank wire by star media llc for a two day investor relations campaign of STEM. SCS LLC does not hold any positions in STEM. SCS LLC has previously been compensated twenty thousand dollars cash via bank wire by DF Media for the mention of MGT. We do not hold any positions in MGT. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. We have not been compensated nor do we own positions in the company/companies that are in the featured article.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
Please Note: We do NOT accept free trading or restricted securities as payment for our services.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.